Puma Biotechnology Inc (PBYI) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

13/25

Growth 4 Margin 2 Expansion 3 Platform 0 Financial 4

latest quarter score

Earnings Reports

13
Puma Biotechnology (PBYI) Q2 2026: Nearlink U.S. Sales Jump 28%, Fueling Positive Net Income and R&D Expansion
August 07, 2026
17
Puma Biotechnology (PBYI) Q1 2026: Dose-Escalation Drives 25% New Rx Surge, Biomarker Focus Sharpens Pipeline
May 08, 2026
9
Puma Biotechnology (PBYI) Q3 2025: U.S. Nerlynx Sales Rise 6% as R&D Spend Accelerates
November 07, 2025
11
Puma Biotechnology (PBYI) Q2 2025: Neuralink Sales Up 12%, R&D Investment Signals Pipeline Acceleration
August 08, 2025
12
Puma Biotechnology (PBYI) Q1 2025: Product Revenue Growth Contrasted by Seasonal Inventory Drawdown and Clinical Pipeline Progress
May 08, 2025
Puma Biotechnology (PBYI) Q4 2024: Nerlynx Sales Growth Offset by Declining Royalties and Strategic R&D Expansion
February 27, 2025

Browse all companies